POSTN and asthma: Meaningful clinical effects with anti-cytokine-based biologic therapies require carefully selected patient populations that take asthma phenotypes into account, guided by straightforward non-invasive discriminatory biomarkers, such as blood eosinophil counts, FeNO, and serum periostin [25,26].